Stress-activated miR-21/miR-21∗ in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption

Gut

Volumn 65, Issue 11, 2016, Pages 1871-1881

  Calo, Nicolas ^a   Ramadori, Pierluigi ^a   Sobolewski, Cyril ^a   Romero, Yannick ^b   Maeder, Christine ^a   Fournier, Margot ^a   Rantakari, Pia ^c,d   Zhang, Fu Ping ^d   Poutanen, Matti ^d   Dufour, Jean Francois ^e   Humar, Bostjan ^f   Nef, Serge ^b   Foti, Michelangelo ^a  

^a Rue Michel Servet   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; INSULIN RECEPTOR SUBSTRATE 2; MEMBRANE PROTEIN; MICRORNA 21; PROTEIN KINASE B; RAPAMYCIN INSENSITIVE COMPANION OF MAMMALAN TARGET OF RAPAMYCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FAT INTAKE; GLUCOSE; MICRORNA; MIRN21 MICRORNA, MOUSE;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CONTROLLED STUDY; DE NOVO LIPOGENESIS; DIET INDUCED OBESITY; DISEASE ASSOCIATION; ENERGY EXPENDITURE; EX VIVO STUDY; FATTY ACID TRANSPORT; FATTY LIVER; GENE DELETION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GLUCONEOGENESIS; GLUCOSE INTOLERANCE; GLUCOSE METABOLIC DISORDER; GLUCOSE METABOLISM; GLYCOLYSIS; HISTOPATHOLOGY; INSULIN RESISTANCE; INSULIN SENSITIVITY; KNOCKOUT MOUSE; LIPID ANALYSIS; LIPID DIET; LIPID METABOLIC DISORDER; LIPID METABOLISM; LIPOGENESIS; LIVER CELL; METABOLIC DISORDER; METABOLIC REGULATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; UPREGULATION; ADVERSE EFFECTS; ANIMAL; DISEASE MODEL; DISORDERS OF CARBOHYDRATE METABOLISM; FAT INTAKE; METABOLISM; OBESITY; PATHOLOGY;

ANIMALS; DIET, HIGH-FAT; DIETARY FATS; DISEASE MODELS, ANIMAL; FATTY LIVER; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM DISORDERS; HEPATOCYTES; MICE; MICE, KNOCKOUT; MICRORNAS; OBESITY;

EID: 84973390006     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310822     Document Type: Article

References (68)

1. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013;10:330-44.
2. Attar BM, Van Thiel DH. Current concepts and management approaches in nonalcoholic fatty liver disease. Scientific World Journal 2013;2013:481893.
3. Bensinger SJ, Christofk HR. New aspects of the Warburg effect in cancer cell biology. Semin Cell Dev Biol 2012;23:352-61.
4. Biswas S, Lunec J, Bartlett K. Non-glucose metabolism in cancer cells-is it all in the fat Cancer Metastasis Rev 2012;31:689-98.
5. Rottiers V, Näär AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012;13:239-50.
6. Williams MD, Mitchell GM. MicroRNAs in insulin resistance and obesity. Exp Diabetes Res 2012;2012:484696.
7. Lee S, Vasudevan S. Post-transcriptional stimulation of gene expression by microRNAs. Adv Exp Med Biol 2013;768:97-126.
8. Poy MN, Spranger M, Stoffel M. microRNAs and the regulation of glucose and lipid metabolism. Diabetes Obes Metab 2007;9(Suppl 2):67-73.
9. Ceccarelli S, Panera N, Gnani D, et al. Dual role of microRNAs in NAFLD. Int J Mol Sci 2013;14:8437-55.
10. Kaur K, Bhatia H, Datta M. MicroRNAs in hepatic pathophysiology in diabetes. World J Diabetes 2011;2:158-63.
11. Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res 2011;157:241-52.
12. Wong CM, Kai AK, Tsang FH, et al. Regulation of hepatocarcinogenesis by microRNAs. Front Biosci (Elite Ed) 2013;5:49-60.
13. Pan X, Wang Z-X, Wang R. MicroRNA-21: a novel therapeutic target in human cancer. Cancer Biol Ther 2010;10:1224-32.
14. Androsavich JR, Chau BN, Bhat B, et al. Disease-linked microRNA-21 exhibits drastically reduced mRNA binding and silencing activity in healthy mouse liver. RNA 2012;18:1510-26.
15. Adam O, Löhfelm B, Thum T, et al. Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Res Cardiol 2012;107:278.
16. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010;207:1589-97.
17. Patel V, Noureddine L. MicroRNAs and fibrosis. Curr Opin Nephrol Hypertens 2012;21:410-16.
18. Marquez RT, Bandyopadhyay S, Wendlandt EB, et al. Correlation between microRNA expression levels and clinical parameters associated with chronic hepatitis C viral infection in humans. Lab Invest 2010;90:1727-36.
19. Zhang J, Jiao J, Cermelli S, et al. miR-21 inhibition reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ progenitor cells. Cancer Res 2015;75:1859-67.
20. Wang J, Gao Y, Ma M, et al. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem Biophys 2013;67:537-46.
21. Meng F, Henson R, Wehbe-Janek H, et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58.
22. Selaru FM, Olaru AV, Kan T, et al. MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 2009;49:1595-601.
23. Francis H, McDaniel K, Han Y, et al. Regulation of the extrinsic apoptotic pathway by microRNA-21 in alcoholic liver injury. J Biol Chem 2014;289: 27526-39.
24. Wagenaar TR, Zabludoff S, Ahn SM, et al. Anti-miR-21 suppresses hepatocellular carcinoma growth via broad transcriptional network deregulation. Mol Cancer Res 2015;13:1009-21.
25. Ng R, Song G, Roll GR, et al. A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. J Clin Invest 2012;122:1097-108.
26. Yan-nan B, Zhao-yan Y, Li-xi L, et al. MicroRNA-21 accelerates hepatocyte proliferation in vitro via PI3K/Akt signaling by targeting PTEN. Biochem Biophys Res Commun 2014;443:802-7.
27. Mah SM, Buske C, Humphries RK, et al. miRNA∗: a passenger stranded in RNA-induced silencing complex Crit Rev Eukaryot Gene Expr 2010;20:141-8.
28. Ben-Dov IZ, Muthukumar T, Morozov P, et al. MicroRNA sequence profiles of human kidney allografts with or without tubulointerstitial fibrosis. Transplantation 2012;94:1086-94.
29. Bang C, Batkai S, Dangwal S, et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J Clin Invest 2014;124:2136-46.
30. Cheung O, Puri P, Eicken C, et al. Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 2008;48:1810-20.
31. Vickers KC, Shoucri BM, Levin MG, et al. MicroRNA-27b is a regulatory hub in lipid metabolism and is altered in dyslipidemia. Hepatology 2013;57:533-42.
32. Vinciguerra M, Sgroi A, Veyrat-Durebex C, et al. Unsaturated fatty acids inhibit the expression of tumor suppressor phosphatase and tensin homolog (PTEN) via microRNA-21 up-regulation in hepatocytes. Hepatology 2009;49:1176-84.
33. Morrisey EE. The magic and mystery of miR-21. J Clin Invest 2010;120:3817-19.
34. Schuler M, Dierich A, Chambon P, et al. Efficient temporally controlled targeted somatic mutagenesis in hepatocytes of the mouse. Genesis 2004;39:167-72.
35. Jin X, Nowell CS, Ulyanchenko S, et al. Long-term persistence of functional thymic epithelial progenitor cells in vivo under conditions of low FOXN1 expression. PLoS ONE 2014;9:e114842.
36. Hameyer D, Loonstra A, Eshkind L, et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol Genomics 2007;31: 32-41.
37. Peyrou M, Bourgoin L, Poher AL, et al. Hepatic PTEN deficiency improves muscle insulin sensitivity and decreases adiposity in mice. J Hepatol 2015;62:421-9.
38. Ramadori P, Ahmad G, Ramadori G. Cellular and molecular mechanisms regulating the hepatic erythropoietin expression during acute-phase response: a role for IL-6. Lab Inves 2010;90:1306-24.
39. Dweep H, Gretz N. miRWalk2.0: a comprehensive atlas of microRNA-target interactions. Nat Methods 2015;12:697.
40. Zhou J, Wang K-C, Wu W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci USA 2011;108:10355-60.
41. Kida K, Nakajima M, Mohri T, et al. PPAR is regulated by miR-21 and miR-27b in human liver. Pharm Res 2011;28:2467-76.
42. Liu J, Liu W, Ying H, et al. Analysis of microRNA expression profile induced by AICAR in mouse hepatocytes. Gene 2013;512:364-72.
43. Yamada H, Suzuki K, Ichino N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013;424C:99-103.
44. Wu H, Ng R, Chen X, et al. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut 2016;65:1850-60.
45. Ferland-McCollough D, Ozanne SE, Siddle K, et al. The involvement of microRNAs in Type 2 diabetes. Biochem Soc Trans 2010;38:1565-70.
46. Guay C, Roggli E, Nesca V, et al. Diabetes mellitus, a microRNA-related disease Transl Res 2011;157:253-64.
47. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542-52.
48. Sobolewski C, Calo N, Portius D, et al. MicroRNAs in fatty liver disease. Semin Liver Dis 2015;35:12-25.
49. Go H, Jang JY, Kim PJ, et al. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma. Oncotarget 2015;6:15035-49.
50. Larsen L, Rosenstierne MW, Gaarn LW, et al. Expression and localization of microRNAs in perinatal rat pancreas: role of miR-21 in regulation of cholesterol metabolism. PLoS ONE 2011;6:e25997.
51. Kim YJ, Hwang SH, Cho HH, et al. MicroRNA 21 regulates the proliferation of human adipose tissue-derived mesenchymal stem cells and high-fat diet-induced obesity alters microRNA 21 expression in white adipose tissues. J Cell Physiol 2012;227:183-93.
52. Zhao J, Tang N, Wu K, et al. MiR-21 simultaneously regulates ERK1 signaling in HSC activation and hepatocyte EMT in hepatic fibrosis. PLoS ONE 2014;9:e108005.
53. Loyer X, Paradis V, Hénique C, et al. Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARalpha expression. Gut 2016;65:1882-94.
54. Chan SMH, Sun RQ, Zeng XY, et al. Activation of PPAR Ameliorates Hepatic Insulin Resistance and Steatosis in High Fructose-Fed Mice Despite Increased Endoplasmic Reticulum Stress. Diabetes 2013;62:2095-105.
55. Fan W, Imamura T, Sonoda N, et al. FOXO1 transrepresses peroxisome proliferator-activated receptor gamma transactivation, coordinating an insulin-induced feed-forward response in adipocytes. J Biol Chem 2009;284:12188-97.
56. Martinez-Jimenez CP, Kyrmizi I, Cardot P, et al. Hepatocyte nuclear factor 4alpha coordinates a transcription factor network regulating hepatic fatty acid metabolism. Mol Cell Biol 2010;30:565-77.
57. Yecies JL, Zhang HH, Menon S, et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 2011;14:21-32.
58. Connolly E, Melegari M, Landgraf P, et al. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol 2008;173: 856-64.
59. Orellana-Gavaldà JM, Herrero L, Malandrino MI, et al. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology (Baltimore, Md) 2011;53:821-32.
60. Fukushima A, Loh K, Galic S, et al. T-cell protein tyrosine phosphatase attenuates STAT3 and insulin signaling in the liver to regulate gluconeogenesis. Diabetes 2010;59:1906-14.
61. Tripathy S, Jump DB. Elovl5 regulates the mTORC2-Akt-FOXO1 pathway by controlling hepatic cis-vaccenic acid synthesis in diet-induced obese mice. J Lipid Res 2013;54:71-84.
62. Shimomura I, Matsuda M, Hammer RE, et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 2000;6:77-86.
63. Ling HY, Hu B, Hu XB, et al. MiRNA-21 reverses high glucose and high insulin induced insulin resistance in 3T3-L1 adipocytes through targeting phosphatase and tensin homologue. Exp Clin Endocrinol Diabetes 2012;120: 553-9.
64. Ma X, Kumar M, Choudhury SN, et al. Loss of the miR-21 allele elevates the expression of its target genes and reduces tumorigenesis. Proc Natl Acad Sci USA 2011;108:10144-9.
65. Wang B, Hsu SH, Frankel W, et al. Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 2012;56:186-97.
66. El Ouaamari A, Kawamori D, Dirice E, et al. Liver-derived systemic factors drive cell hyperplasia in insulin-resistant states. Cell Rep 2013;3:401-10.
67. Chartoumpekis DV, Zaravinos A, Ziros PG, et al. Differential expression of microRNAs in adipose tissue after long-term high-fat diet-induced obesity in mice. PLoS ONE 2012;7:e34872.
68. Kang M, Yan LM, Zhang WY, et al. Role of microRNA-21 in regulating 3T3-L1 adipocyte differentiation and adiponectin expression. Mol Biol Rep 2013;40:5027-34.